KORU Medical Systems has demonstrated robust top-line growth of 22.2% in 2025, driven by its FREEDOM System platform targeting immunoglobulin therapies for PIDD and CIDP. Despite improved operating margins with a 53.9% reduction in operating losses, the company remains unprofitable at the net income level and navigates challenges from single-source suppliers and distributor concentration risks. Regulatory demands and ongoing R&D investment underscore cautious optimism about future market expansion amid operational constraints.